Lisata Therapeutics (NASDAQ:LSTA) Trading Up 1.4% – Still a Buy?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s share price rose 1.4% during mid-day trading on Wednesday . The stock traded as high as $2.98 and last traded at $2.98. Approximately 45,386 shares changed hands during mid-day trading, an increase of 215% from the average daily volume of 14,403 shares. The stock had previously closed at $2.94.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Lisata Therapeutics in a research note on Wednesday, December 11th.

Lisata Therapeutics Price Performance

The business’s 50 day simple moving average is $2.83 and its 200 day simple moving average is $3.04. The stock has a market cap of $25.02 million, a P/E ratio of -1.19 and a beta of 1.16.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.16. During the same period in the prior year, the company posted ($0.65) EPS. Research analysts predict that Lisata Therapeutics, Inc. will post -2.66 earnings per share for the current year.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.